AnaptysBio Aktie
WKN DE: A2AJ8C / ISIN: US0327241065
23.08.2024 13:26:56
|
Why AnaptysBio Was Such a Healthy Stock This Week
Clinical-stage biotech AnaptysBio (NASDAQ: ANAB) has recently been something of a standout, at least on the stock exchange. According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's share price had increased by nearly 10% week to date as of Friday before market open. Although there was little market-moving direct news from the company, a positive research note published Monday brought investors into the stock.The analyst behind that note, Guggenheim's Yatin Suneja, reiterated his buy rating on AnaptysBio. He also maintained his $75-per-share price target, which is slightly more than double the stock's latest closing price.Suneja's latest note on the biotech follows Guggenheim's hosting of a set of investor meetings with company management. In these, the pundit found several reasons to keep his positive take intact. He said a phase 2 clinical trial of AnaptysBio's investigational atopic dermatitis drug should produce a readout in December, with company officials apparently confident in the outcome.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AnaptysBio Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu AnaptysBio Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
AnaptysBio Inc Registered Shs | 16,80 | -2,89% |
|